glycine-N-acyltransferase like 3Genealiases: C6orf140 · bA28H17.2
Q-omics provides the consensus-scored GLYATL3 profile across patient tissues and cancer cell-line models. GLYATL3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, GLYATL3 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, GLYATL3 RNA expression shows 6,571 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, COAD, and STAD as cancer lineages where GLYATL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLYATL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLYATL3 survival associations across molecular data types. GLYATL3 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLYATL3 RNA expression–survival associations across cancer types. High GLYATL3 expression shows unfavorable associations in ESCA, READ, KIRC and LUSC, but favorable associations in PAAD and OV. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for GLYATL3 RNA expression.
This table summarizes GLYATL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GLYATL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLYATL3 shows lower tumor expression in COAD, LIHC, READ, THCA and KICH and higher tumor expression in UCEC. The COAD box plot shows higher GLYATL3 RNA expression in normal versus tumor tissue (log2 FC = −0.334, t-test p < 0.001).
This table shows molecular features associated with GLYATL3 in patient tissues and cancer cell lines. In patient samples, GLYATL3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GLYATL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LIVER and KIDNEY.
